Comparative Pharmacology
Head-to-head clinical analysis: BRISTAGEN versus TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRISTAGEN versus TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
BRISTAGEN vs TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bristagen (amikacin) is an aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
Tobramycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis in susceptible bacteria.
1-2 mg/kg IM or IV every 8-12 hours; typical adult dose is 1 mg/kg every 8 hours.
3-5 mg/kg/day IV divided every 8 hours or 5-7 mg/kg IV once daily for adults with normal renal function.
None Documented
None Documented
2.5 hours (prolonged to 20-40 hours in renal impairment).
2-3 hours in patients with normal renal function; prolonged to 24-60 hours in anuria. Half-life is directly correlated with creatinine clearance.
Renal (90% unchanged via glomerular filtration); biliary/fecal excretion <10%.
Primarily renal (glomerular filtration) with >90% excreted unchanged in urine within 24 hours; minimal biliary/fecal (<1%).
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic